NIH VideoCast - Pharmacogenomics

Skip Navigation

Pharmacogenomics

Loading... Loading video...

Air date:	Friday, January 11, 2008, 10:00:00 AM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 109 * This only includes stats from October 2011 and forward.
Category:	Special
Runtime:	01:25:00
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	OPASI ROUNDS Lecture Series Administration of virtually any drug to a group of patient’s results in a spectrum of responses: some patients may derive great benefit, in others there is no effect, and some patients will have adverse effects. The concept that such variability in drug response might include a heritable component goes back over 100 years. The identification of responsible variants in individual genes, and the sequencing of the human genome and its variants now opens the door to an era of personalized prescribing in which genomic information becomes a routine component of clinical decision-making. This talk will highlight current evidence linking genomic variants to variable drug responses, and will describe obstacles – and their potential solutions – to the implementation of such a personalized prescribing future. The Office of Portfolio Analysis and Strategic Initiatives (OPASI) provides the National Institutes of Health (NIH) and its constituent Institutes and Centers (ICs) with the methods and information necessary to manage their large and complex scientific portfolios, identifies – in concert with multiple other inputs – important areas of emerging scientific opportunities or rising public health challenges, and assists in the acceleration of investments in these areas, focusing on those involving multiple ICs.

NLM Title:	Pharmacogenomics / Dan Roden.
Author:	Roden, D M. National Institutes of Health (U.S.)
Publisher:
Abstract:	(CIT) Administration of virtually any drug to a group of patient's results in a spectrum of responses: some patients may derive great benefit, in others there is no effect, and some patients will have adverse effects. The concept that such variability in drug response might include a heritable component goes back over 100 years. The identification of responsible variants in individual genes, and the sequencing of the human genome and its variants now opens the door to an era of personalized prescribing in which genomic information becomes a routine component of clinical decision-making. This talk will highlight current evidence linking genomic variants to variable drug responses, and will describe obstacles and their potential solutions to the implementation of such a personalized prescribing future. The Office of Portfolio Analysis and Strategic Initiatives (OPASI) provides the National Institutes of Health (NIH) and its constituent Institutes and Centers (ICs) with the methods and information necessary to manage their large and complex scientific portfolios, identifies in concert with multiple other inputs important areas of emerging scientific opportunities or rising public health challenges, and assists in the acceleration of investments in these areas, focusing on those involving multiple ICs.
Subjects:	Pharmaceutical Preparations Pharmacogenetics--trends
Publication Types:	Lecture Webcast
NLM Classification:	QV 38
NLM ID:	101465462
CIT Live ID:	6091
Permanent link:	https://videocast.nih.gov/watch=6091

Related Videos...